250 related articles for article (PubMed ID: 15934857)
1. ICH S7B draft guideline on the non-clinical strategy for testing delayed cardiac repolarisation risk of drugs: a critical analysis.
Cavero I; Crumb W
Expert Opin Drug Saf; 2005 May; 4(3):509-30. PubMed ID: 15934857
[TBL] [Abstract][Full Text] [Related]
2. Drugs, QTc interval prolongation and final ICH E14 guideline : an important milestone with challenges ahead.
Shah RR
Drug Saf; 2005; 28(11):1009-28. PubMed ID: 16231954
[TBL] [Abstract][Full Text] [Related]
3. Drugs, QT interval prolongation and ICH E14: the need to get it right.
Shah RR
Drug Saf; 2005; 28(2):115-25. PubMed ID: 15691222
[TBL] [Abstract][Full Text] [Related]
4. Safety pharmacology in focus: new methods developed in the light of the ICH S7B guidance document.
Pugsley MK; Curtis MJ
J Pharmacol Toxicol Methods; 2006; 54(2):94-8. PubMed ID: 16806993
[TBL] [Abstract][Full Text] [Related]
5. Non-clinical evaluation of ventricular repolarization (ICH S7B): results of an interim survey of international pharmaceutical companies.
Friedrichs GS; Patmore L; Bass A
J Pharmacol Toxicol Methods; 2005; 52(1):6-11. PubMed ID: 15975833
[TBL] [Abstract][Full Text] [Related]
6. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline.
Darpo B; Nebout T; Sager PT
J Clin Pharmacol; 2006 May; 46(5):498-507. PubMed ID: 16638733
[TBL] [Abstract][Full Text] [Related]
7. Translational Models and Tools to Reduce Clinical Trials and Improve Regulatory Decision Making for QTc and Proarrhythmia Risk (ICH E14/S7B Updates).
Strauss DG; Wu WW; Li Z; Koerner J; Garnett C
Clin Pharmacol Ther; 2021 Feb; 109(2):319-333. PubMed ID: 33332579
[TBL] [Abstract][Full Text] [Related]
8. [Draft ICH guideline S7B: guideline on safety pharmacology studies for assessing the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals].
Hashimoto M
Nihon Yakurigaku Zasshi; 2003 Jun; 121(6):377-83. PubMed ID: 12835531
[TBL] [Abstract][Full Text] [Related]
9. A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay Paradigm.
Fermini B; Hancox JC; Abi-Gerges N; Bridgland-Taylor M; Chaudhary KW; Colatsky T; Correll K; Crumb W; Damiano B; Erdemli G; Gintant G; Imredy J; Koerner J; Kramer J; Levesque P; Li Z; Lindqvist A; Obejero-Paz CA; Rampe D; Sawada K; Strauss DG; Vandenberg JI
J Biomol Screen; 2016 Jan; 21(1):1-11. PubMed ID: 26170255
[TBL] [Abstract][Full Text] [Related]
10. A Historical View and Vision into the Future of the Field of Safety Pharmacology.
Bass AS; Hombo T; Kasai C; Kinter LB; Valentin JP
Handb Exp Pharmacol; 2015; 229():3-45. PubMed ID: 26091634
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive in vitro Proarrhythmia Assay, a novel in vitro/in silico paradigm to detect ventricular proarrhythmic liability: a visionary 21st century initiative.
Cavero I; Holzgrefe H
Expert Opin Drug Saf; 2014 Jun; 13(6):745-58. PubMed ID: 24845945
[TBL] [Abstract][Full Text] [Related]
12. Cardiac safety strategies. 25-26 October 2005, the Radisson SAS Hotel, Nice, France.
Hanton G; Tilbury L
Expert Opin Drug Saf; 2006 Mar; 5(2):329-33. PubMed ID: 16503752
[TBL] [Abstract][Full Text] [Related]
13. Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug safety screening?
Towart R; Linders JT; Hermans AN; Rohrbacher J; van der Linde HJ; Ercken M; Cik M; Roevens P; Teisman A; Gallacher DJ
J Pharmacol Toxicol Methods; 2009; 60(1):1-10. PubMed ID: 19439185
[TBL] [Abstract][Full Text] [Related]
14. Best practice considerations for nonclinical in vivo cardiovascular telemetry studies in non-rodent species: Delivering high quality QTc data to support ICH E14/S7B Q&As.
Rossman EI; Wisialowski TA; Vargas HM; Valentin JP; Rolf MG; Roche BM; Riley S; Pugsley MK; Nichols J; Li D; Leishman DJ; Kleiman RB; Greiter-Wilke A; Gintant GA; Engwall MJ; Delaunois A; Authier S
J Pharmacol Toxicol Methods; 2023; 123():107270. PubMed ID: 37164235
[TBL] [Abstract][Full Text] [Related]
15. Scientific Review of the Proarrhythmic Risks of Oligonucleotide Therapeutics: Are Dedicated ICH S7B/E14 Studies Needed for Low-Risk Modalities?
Qu Y; Henderson KA; Harper TA; Vargas HM
Clin Pharmacol Ther; 2024 Jul; 116(1):96-105. PubMed ID: 38362953
[TBL] [Abstract][Full Text] [Related]
16. Benchmarking safety pharmacology regulatory packages and best practice.
Lindgren S; Bass AS; Briscoe R; Bruse K; Friedrichs GS; Kallman MJ; Markgraf C; Patmore L; Pugsley MK
J Pharmacol Toxicol Methods; 2008; 58(2):99-109. PubMed ID: 18692579
[TBL] [Abstract][Full Text] [Related]
17. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
Pflieger M; Bertram D
Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
[TBL] [Abstract][Full Text] [Related]
18. Assessment of QT liabilities in drug development.
Arrigoni C; Crivori P
Cell Biol Toxicol; 2007 Jan; 23(1):1-13. PubMed ID: 17013551
[TBL] [Abstract][Full Text] [Related]
19. ICH topic: the draft ICH S7B step 2: note for guidance on safety pharmacology studies for human pharmaceuticals.
Bode G; Olejniczak K;
Fundam Clin Pharmacol; 2002 Apr; 16(2):105-18. PubMed ID: 12031063
[TBL] [Abstract][Full Text] [Related]
20. International Conference on Harmonisation; guidance on S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2005 Oct; 70(202):61133-4. PubMed ID: 16237859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
